IngredientsAlpha-D-ribofuranose is a monosaccharide (simple sugar) and a specific cyclic form of D-ribose, a five-carbon (pentose) sugar that plays a central role in nucleic acid chemistry and cellular energy metabolism. The "alpha" designation refers to the orientation of the hydroxyl group on the anomeric carbon (carbon-1) in the furanose (five-membered ring) structure, distinguishing it from the beta form.
Its molecular formula is C₅H₁₀O₅ and it is assigned PubChem Compound ID (CID) 445894. It is recorded in ChemSpider under the IUPAC name α-D-Ribofuranose with the InChIKey HMFHBZSHGGEWLO-AIHAYLRMSA-N. The compound carries CAS registry number 32445-75-3 in its discrete alpha-anomer form.
Ribose is an aldopentose — a monosaccharide containing five carbon atoms that, in its open chain form, has an aldehyde functional group at one end. Its structure features a five-membered ring, known as a furanose form, making it distinct from other sugars like glucose. D-ribose exists in equilibrium between linear and cyclic structures, but the furanose ring is predominant in biological systems, especially in RNA (ribonucleic acid).
Common synonyms include: D-ribofuranose (the general cyclic form, CID 5779), D-ribose, and ribose. D-ribose is a five-carbon sugar with strong water solubility and sweet taste, also known as D-ribofuranose.
It is essential to understand the relationship between alpha-D-ribofuranose and the compound marketed as a dietary supplement. Alpha-D-ribofuranose is the predominant ring form that D-ribose naturally adopts in aqueous biological environments. There are two forms of the sugar ribose: L-ribose and D-ribose. L-ribose is man-made (non-natural), but the body makes D-ribose. When D-ribose is dissolved in water — as in an oral supplement — it spontaneously equilibrates primarily into the furanose ring conformation. Therefore, all scientific and clinical literature discussing supplemental "D-ribose" refers to the same substance as alpha-D-ribofuranose, and both names are used throughout this article to reflect the relevant literature.
D-ribose is a naturally occurring monosaccharide found in the cells and particularly in the mitochondria, where it is essential in energy production. It can also be obtained from natural sources, such as yeast and some plants, where it exists as part of larger biomolecules.
Ribose has been reported found in boiled crab, hen egg, catfish, whitefish, haddock, stored beef, stored veal, milk, applesauce, potato, rapeseed, roasted coffee, fresh coffee, and shrimp. Ribose has also been detected in meteorites, underscoring its fundamental role in prebiotic chemistry.
Ribose as its 5-phosphate ester is typically produced endogenously from glucose by the pentose phosphate pathway. Ribose can be synthesized chemically, but commercial production relies on fermentation of glucose. Using genetically modified strains of B. subtilis, 90 g/liter of ribose can be produced from 200 g of glucose. More specifically, the commercially available supplement product Bioenergy Ribose™ is manufactured via a distinct microbial method: the product is produced by fermentation using a transketolase-deficient strain of Bacillus subtilis.
D-ribose is taken in tablets/capsules or loose powder dissolved in water. As a food ingredient, it has been evaluated by regulators for use in a range of food matrices. The applicant for EU novel food authorization intends to market the product as an ingredient in a variety of foods, food supplements, and in certain foods for specific groups. D-ribose may also be supplemented intravenously, via oral therapy, or via other exogenous means, and is utilized in several scenarios, including the clinic, in athletes, and in healthcare.
Alpha-D-ribofuranose as a discrete compound has no known use in traditional herbal or folk medicine, as its structure and function were only understood through advances in 20th-century carbohydrate and nucleic acid chemistry. The discovery of ribose dates to 1891, when German chemist Emil Fischer first isolated it during his pioneering work on sugar chemistry. The specific cyclic form — alpha-D-ribofuranose — was identified later as a key sugar in nucleotides and RNA, forming the basis of molecular biology as we know it today.
The therapeutic applications of supplemental D-ribose emerged from mid-twentieth-century biochemical research into purine nucleotide metabolism, myocardial energy depletion during ischemia, and ATP synthesis pathways. NAD, FAD, and NADP act as electron acceptors in biochemical redox reactions in major metabolic pathways including glycolysis, the citric acid cycle, fermentation, and the electron transport chain. Nucleotides are synthesized through salvage or de novo synthesis. The recognition that ribose availability could be rate-limiting in adenine nucleotide re-synthesis opened the door to its study as a therapeutic and ergogenic agent from the 1980s onward.
Alpha-D-ribofuranose is a core structural component of RNA, where it forms part of the backbone of the nucleotides (e.g., adenosine, guanosine, cytidine, uridine). It is also found in nucleotide-based coenzymes such as NAD⁺, FAD, and ATP, and is critical for various biosynthetic and energy-transfer reactions. Metabolically important species that include phosphorylated ribose include ADP, ATP, coenzyme A, and NADH. cAMP and cGMP serve as secondary messengers in some signaling pathways and are also ribose derivatives.
The pentose phosphate pathway (PPP) is the major source of NADPH for reductive biosynthesis and is the source of ribose-5-phosphate for nucleotide and nucleic acid synthesis. It has two important products: ribose 5-phosphate, which is needed for synthesis of nucleotides and nucleic acids (DNA and RNA), and NADPH, which provides the reducing equivalents for synthetic reactions such as fatty acid biosynthesis.
D-ribose is synthesized from glucose via the PPP within the cell. This process begins with D-glucose as a precursor for D-ribose synthesis, which undergoes phosphorylation to form glucose-6-phosphate (G-6-P). Subsequently, G-6-P is oxidized to 5-phosphate ribulose (Ru-5-P) along with NADPH through the oxidative phase of the PPP.
The proposed mechanism underlying supplemental D-ribose's therapeutic effects centers on its role as a direct precursor to phosphoribosylpyrophosphate (PRPP), which is the rate-limiting substrate for adenine nucleotide synthesis. Within the cellular milieu, exogenously supplied D-ribose can undergo phosphorylation to yield ribose-5-phosphate (R-5-P). This R-5-P compound serves a dual purpose: it not only contributes to ATP production through the nonoxidative phase of the PPP but also participates in nucleotide synthesis.
Some of the loss of adenine nucleotides will be countered by nucleotide salvage pathways, but the total adenine nucleotide (TAN) pool is also replenished by continuous low-level de novo purine synthesis. Phosphoribosylpyrophosphate (PRPP) is the common substrate for both these pathways and is generated from ribose-5-phosphate via the action of PRPP synthetase. Under certain conditions, ribose-5-phosphate availability via the pentose phosphate pathway can be limiting, and this can be circumvented by administration of exogenous D-ribose.
Ribose 5-phosphate is not used directly for either purine or pyrimidine synthesis; rather, it is used to synthesize the "active pentose" — 5-phosphoribosyl-1-pyrophosphate (PRPP). The conversion is catalyzed by the enzyme PRPP synthase. PRPP is the activated five-carbon sugar used for nucleotide synthesis and provides both the sugar and phosphate group to nucleotides.
Supplemental ribose enters the PPP, bypassing the rate-limiting steps, leading to the formation of adenine nucleotides.
D-ribose, via increasing the recovery of myocardial energy, reduces the activation of NF-κB by oxygen free radicals such as hydrogen peroxide, thereby decreasing the expression of chemokines in activated neutrophils and significantly attenuating the activation, infiltration, and degranulation of neutrophils, as well as reducing the release of myeloperoxidase in myocardial tissues. The activity of other myocardial enzymes is significantly reduced, thus significantly reducing the inflammatory response.
D-ribose may participate in protein glycation leading to cell cytotoxicity. Glycation can cause the production of reactive oxygen species (ROS) and advanced glycation end-products (AGEs) that can accumulate and form protein aggregates. D-ribose can lead to the glycosylation of HbA1c and AGEs, which both contribute to the development of diabetic-associated complications. This glycation activity has been proposed to be relevant at elevated, pathological concentrations of D-ribose, and forms an area of ongoing scientific investigation regarding the compound's dual role as both an energy substrate and a potential pro-glycating agent.
Clinical trials have shown that ribose supplementation improves ischemic threshold and enhances diastolic function in congestive heart failure. Currently, there are no effective treatments specifically for heart failure with preserved ejection fraction (HFpEF), thus clinicians and researchers are searching for therapies to improve cardiac function. Emerging evidence indicates that mitochondrial dysfunction and impaired cardiac bioenergetics are among the underlying mechanisms for HFpEF. There is increased interest in investigating the use of supplements such as D-ribose to enhance mitochondrial function and improve production of adenosine triphosphate (ATP).
The landmark clinical human study in this area is a prospective feasibility trial published in 2003. This was a prospective, double-blind, randomized, crossover design study to assess the effect of oral D-ribose supplementation on cardiac hemodynamics and quality of life in 15 patients with chronic coronary artery disease and congestive heart failure (CHF). The study consisted of two treatment periods of 3 weeks, during which either oral D-ribose or placebo was administered followed by a 1-week washout period, and then administration of the other supplement. Assessment of myocardial functional parameters by echocardiography, quality of life using the SF-36 questionnaire, and functional capacity using cycle ergometer testing was performed.
The administration of D-ribose resulted in an enhancement of atrial contribution to left ventricular filling (40±11 vs. 45±9%, P=0.02), a smaller left atrial dimension (54±20 vs. 47±18 ml, P=0.02), and a shortened E wave deceleration (235±64 vs. 196±42, P=0.002) by echocardiography. Further, D-ribose also demonstrated a significant improvement of the patient's quality of life (417±118 vs. 467±128, P≤0.01). In comparison, placebo did not result in any significant echocardiographic changes or in quality of life. This feasibility study in patients with coronary artery disease in CHF revealed the beneficial effects of D-ribose by improving diastolic functional parameters and enhancing quality of life.
There is a recently completed clinical trial with HFpEF patients that indicates D-ribose increases ATP production and improves cardiac ejection fraction. A study by Pliml et al. found that patients with severe coronary artery disease who consumed D-ribose for 3 days had improved myocardial tolerance to ischemia. They hypothesized that supplemental D-ribose increased ATP metabolism and assisted with restoring cardiac energy metabolism.
Evidence strength assessment: The clinical data for D-ribose in CHF are characterized by researchers as "compelling, but preliminary." The key human study enrolled only 15 patients, and larger randomized controlled trials are lacking. It is essential to find potential targeted therapeutic treatments for HFpEF. Since there is evidence that HFpEF is related to impaired myocardial bioenergetics, enhancing mitochondrial function could augment cardiac function. Using a supplement such as D-ribose could improve mitochondrial function by increasing ATP and enhancing cardiac performance for patients with HFpEF. Overall, existing human evidence is suggestive but insufficiently powered to constitute conclusive proof; the cardiovascular findings represent preliminary-to-moderate strength evidence requiring confirmation in larger trials.
Oral D-ribose supplementation has been reported to increase adenine nucleotide synthesis and exercise capacity in certain clinical populations. Theoretically, increasing adenine nucleotide availability may enhance high-intensity exercise capacity.
A randomized, double-blind study by Kreider et al. evaluated the ergogenic potential of D-ribose in 19 trained males. Subjects were assigned in a randomized and double-blind manner to ingest capsules containing either 5 g of a dextrose placebo or D-ribose twice daily (10 g/day) for 5 days. Results revealed a significant interaction (p=0.04) in total work output. Post-hoc analysis revealed that work significantly declined (−18±51 J) during the second post-supplementation sprint in the placebo group while being maintained in the D-ribose group (−0.0±31 J). No significant interactions were observed in peak power, average power, torque, fatigue index, lactate, ammonia, glucose, or uric acid.
A double-blind, crossover study by Seifert et al. (2017) in 26 healthy subjects compared 10 g/day of D-ribose to 10 g/day of dextrose. Subjects completed 2 days of loading with either D-ribose or dextrose, followed by 3 additional days of supplementation during which each subject underwent 60 minutes of high-intensity interval exercise. Subjects were divided into two groups based on peak VO₂ results, lower VO₂ (LVO₂) and higher peak VO₂ (HVO₂). Mean and peak power output increased significantly from day 1 to day 3 for the D-ribose trial compared to dextrose in the LVO₂ group. Rate of perceived exertion (RPE) and creatine kinase (CK) were significantly lower for D-ribose than dextrose in the LVO₂ group. Notably, this benefit was not observed in the higher VO₂ group, suggesting that D-ribose may be more effective in less-trained individuals.
A study on resynthesis of adenine nucleotides using ribose at a dose of 200 mg/kg body weight after intense intermittent exercise included 8 subjects in a random, double-blind crossover design. The effect of oral ribose supplementation on the resynthesis of adenine nucleotides and performance was examined after 1 week of intense intermittent exercise. Eight subjects performed cycle training consisting of 15×10 seconds of all-out sprinting twice per day for 7 days. After training, subjects received either ribose (200 mg/kg body weight) or placebo three times per day for 3 days. An exercise test was performed at 72 h after the last training session. Immediately after the last training session, muscle ATP was lowered by 25±2% and 22±3% in placebo and ribose groups, respectively. In both groups, muscle ATP levels at 5 and 24 hours after exercise were still lower than pre-training.
Evidence strength assessment: The totality of evidence for ergogenic effects of D-ribose in healthy, well-trained athletes is weak to mixed. The benefits in sports medicine have not been as obvious as those seen in cardiovascular populations. Individual studies show modest and inconsistent effects. Supplementing with ribose might improve symptoms of heart failure and some aspects of exercise recovery, but more research is needed to understand its efficacy fully.
Fibromyalgia (FMS) and chronic fatigue syndrome (CFS) are debilitating syndromes that are often associated with impaired cellular energy metabolism. D-ribose has been shown to increase cellular energy synthesis in heart and skeletal muscle, and an open-label uncontrolled pilot study was conducted to evaluate if D-ribose could improve symptoms in fibromyalgia and/or chronic fatigue syndrome patients.
Forty-one patients with a diagnosis of FMS and/or CFS were given D-ribose at a dose of 5 g three times daily for a total of 280 g. All patients completed questionnaires containing discrete visual analog scales and a global assessment pre- and post-D-ribose administration. D-ribose, which was well-tolerated, resulted in a significant improvement in all five visual analog scale (VAS) categories: energy; sleep; mental clarity; pain intensity; and well-being, as well as an improvement in patients' global assessment.
It has been postulated that patients with fibromyalgia may have an alteration in muscle adenine nucleotide metabolism, leading to depleted energy reserves and an imbalance in cellular ATP:ADP:AMP ratios with an abnormal energy charge. As a key component in adenine nucleotide synthesis, ribose supplementation may be useful in such patients.
Evidence strength assessment: The evidence for D-ribose in fibromyalgia and CFS is very preliminary. The primary human study is an open-label, uncontrolled pilot with no placebo group, making it impossible to separate specific effects from placebo responses. Future placebo-controlled, double-blind studies are necessary in a larger population to confirm this benefit beyond this open-label trial.
Myoadenylate deaminase deficiency (MADD) is a metabolic muscle disease that interferes with the processing of ATP by muscle cells. Symptoms can include cramps, muscle pain, and exercise intolerance. For people struggling with MADD, there is some evidence that taking D-ribose by mouth or receiving it intravenously may effectively prevent symptoms such as cramping, pain, and stiffness after exercise. The underlying rationale is that in MADD, the purine nucleotide cycle is impaired, and ribose supplementation may partially compensate by providing substrate for adenine nucleotide re-synthesis. This evidence is limited to small clinical reports and case series.
D-ribose is employed both as a therapeutic agent for enhancing cardiac function in heart failure patients and as a remedy for post-exercise fatigue. Nevertheless, recent clinical studies have suggested a potential link between D-ribose metabolic disturbances and type 2 diabetes mellitus (T2DM) along with its associated complications.
Elevated endogenous D-ribose levels have been investigated as a potential contributor to diabetic complications via glycation. The production of formaldehyde is triggered by high concentrations of D-ribose and a condition of pH >7 via the retro aldol reaction in nerve cells, which is one of the mechanisms leading to diabetic encephalopathy. The presence of high concentrations of D-ribose can act as an activation signal, leading to the release of NLRP3 inflammatory bodies from lysosomes, thereby promoting the occurrence of diabetic kidney disease. This is caused by gradual renal fibrosis induced by the release of the pro-inflammatory cytokine IL-1β.
Evidence strength assessment: The evidence linking supplemental D-ribose to beneficial effects in diabetes management is absent; conversely, the evidence linking elevated D-ribose levels to diabetic complications is largely preclinical and mechanistic. Clinical significance in the context of supplementation at standard doses remains to be established.
A double-blind, randomized, crossover pharmacokinetic study evaluated absorption, dose proportionality, food effects, and pharmacodynamics in 12 healthy adult subjects administered D-ribose powder for oral solution at doses of 2.5, 5.0, and 10.0 g under fasting conditions. D-ribose was absorbed rapidly with mean Tmax ranging between 18 and 30 minutes. Cmax and AUC increased more than proportionally with dose, indicating increased absorption and saturation of metabolism.
When D-ribose was administered with meals, Tmax was unchanged; however, Cmax and AUC decreased by 42.6% and 40.8%, respectively, with a high-fat meal, and by 69.1% and 64.9%, respectively, with a high-carbohydrate meal. The amount of D-ribose in urine ranged from 4.15% to 7.20% of the administered dose, indicating that the majority of absorbed ribose undergoes metabolic conversion rather than renal excretion.
Some evidence shows that the rapid absorption of orally ingested ribose is blunted when co-ingested with a high-fat or high-carbohydrate meal, a finding with practical implications for supplement timing.
The following dosage information is drawn exclusively from published clinical study reports:
In the scientific opinion, the EFSA NDA Panel concluded that the novel food was safe for the general population at intake levels up to 36 mg/kg body weight (bw) per day, based on the no-observed-adverse-effect level (NOAEL) of 3.6 g/kg bw per day derived from a subchronic toxicity study in Wistar rats and an uncertainty factor of 100. The Panel concludes that D-ribose is safe under the new proposed conditions of use. However, if used in conjunction with food supplements containing D-ribose, the Panel noted that the acceptable level of intake (36 mg/kg bw per day) may be exceeded.
The Panel considered that the effects observed in a subchronic toxicity study in rats could be the consequence of nutritional imbalances, but toxicological effects could not be ruled out; from this study, the Panel derived a NOAEL of 3.6 g/kg body weight per day. From human studies indicating a potential decrease in glucose levels and/or the occurrence of transient symptomatic hypoglycaemia at intakes of 10 g of D-ribose, the Panel defined 70 mg/kg bw per day as the NOAEL with respect to hypoglycaemia applicable for adults.
The European Food Safety Authority (EFSA) suggests no more than 10 grams a day as a practical upper intake guidance for food fortification contexts. Long-term safety studies have not been done.
The most consistently reported and clinically significant adverse effect is a transient reduction in blood glucose. The administration of single oral doses of 2–87 g D-ribose consistently reports transient decreases of glucose concentrations within 1–3 h. The transient decrease of glucose concentration was not associated with clinical symptoms of hypoglycaemia, except for one case, where a low-weight female experienced short-term symptoms of hypoglycaemia after ingesting 10 g of ribose in the fasted state. While in most studies blood glucose levels did not fall below 2.8 mmol/L, a temporary significant decline of blood glucose to 2.6 mmol/L was observed in one study following a single oral dose of 10 g D-ribose.
The decrease in blood glucose is accompanied by increases in insulin levels. The glucose-lowering effect occurs even if meals rich in carbohydrate or fat are ingested before uptake of D-ribose.
It is well known that bolus oral D-ribose can induce a dose-dependent transient hypoglycaemia that is preceded by a transient spike in insulin levels. This can result in symptomatic hypoglycaemia in subjects whose blood glucose levels fall sufficiently far. This transient hypoglycaemia is the dose-limiting side effect of D-ribose treatment, although it is readily overcome by drinking a glass of fruit juice.
D-ribose produced an asymptomatic, mild hypoglycaemia of short duration. Uric acid levels increased at Day 7 but decreased to baseline values by Day 14.
D-ribose side effects include diarrhea, nausea, headache, and stomach discomfort. These effects were generally mild and transient in the reported clinical studies.
Both ATP-generating pathways can supply ATP for the cells to facilitate their growth. However, when excessive D-ribose is deposited in the cell, it can also initiate rapid nonenzymatic glycation reactions producing AGEs, which can cause damage to the cells. Recent clinical studies have suggested a potential link between D-ribose metabolic disturbances and type 2 diabetes mellitus along with its associated complications. Additionally, certain in vitro experiments have indicated that exogenous D-ribose exposure could trigger apoptosis in specific cell lines.
The risk of hypoglycaemia may be higher in people taking high doses of ribose, those who already have low blood sugar levels, or those who are using medicines that lower blood sugar levels, such as insulin.
D-ribose may not be safe for people with diabetes. If you have diabetes, the sugar may complicate diabetes and raise HbA1c. And with diabetes medicine, ribose may also lower blood sugar (hypoglycaemia).
Supplementation with ribose should be avoided during pregnancy and breastfeeding due to its blood-glucose-lowering effect. People with myalgic encephalomyelitis (chronic fatigue syndrome), diabetes, or gout should be cautious when taking ribose supplements.
In a safety study, 20 grams of oral D-ribose per day for 14 days in healthy subjects did not elicit significant adverse haematological or biochemical abnormalities. However, a mild state of hypoglycaemia and hyperuricaemia can be observed after oral consumption.
Health conditions that Alpha D-ribofuranose may help support.
A 1992 randomized placebo-controlled crossover trial in 20 men with severe coronary artery disease showed that oral D-ribose (60 g/day for 3 days) significantly increased treadmill walk time to 1 mm ST-segment depression and delayed the onset of angina versus placebo. A later randomized double-blind trial confirmed D-ribose plus creatine improved exercise tolerance in ischemic heart disease.
Studies on D-ribose and athletic performance show mixed results. Some trials report maintained or improved ATP levels and power output in exercising subjects, while others show no performance advantage over placebo. Effects appear more pronounced in untrained individuals or those recovering from intense exercise.
In the 2006 (n=41) and 2012 (n=257) open-label CFS/FMS studies, D-ribose at 15 g/day produced statistically significant improvements in self-reported mental clarity alongside energy and pain outcomes. The brain's high ATP demand provides mechanistic plausibility. No RCTs targeting brain fog specifically have been conducted.
D-ribose is the structural precursor to ATP and directly supports cellular energy production by providing substrate for the de novo and salvage purine nucleotide synthesis pathways. Clinical studies in cardiac, CFS, and exercise populations document ATP-replenishing effects. This is the primary documented mechanism of D-ribose supplementation.
Two clinical studies — a 2006 pilot (n=41) and a 2012 multicenter trial (n=257) — found D-ribose at 15 g/day produced marked improvements in energy, pain, sleep, and overall well-being in CFS/fibromyalgia patients. Both studies were open-label and uncontrolled, but the findings were consistent across populations. CFS is theorized to involve impaired mitochondrial ATP metabolism, providing a mechanistic rationale.
D-ribose (alpha-D-ribofuranose) is a structural component of ATP and accelerates adenine nucleotide resynthesis via the pentose phosphate pathway. Two open-label clinical studies in CFS/fibromyalgia patients reported average energy increases of 45–61% on visual analog scales at doses of 15 g/day. Evidence in healthy populations is more limited and mixed.
D-ribose at 15 g/day was studied in 41 fibromyalgia/CFS patients (2006 pilot) and 257 patients (2012 multicenter trial), both reporting significant improvements in pain, energy, sleep, and well-being. Both studies were open-label without placebo controls. Fibromyalgia is associated with impaired cellular energy metabolism, which provides a mechanistic rationale.
Multiple clinical trials demonstrate D-ribose improves diastolic function, exercise tolerance, and quality of life in patients with coronary artery disease and congestive heart failure by restoring depleted myocardial ATP. Evidence is strongest in ischemic and failing hearts; effects in healthy hearts are undemonstrated.
D-ribose's documented role in restoring myocardial ATP and improving diastolic function in heart failure patients has indirect relevance to heart rhythm, since ATP depletion and diastolic dysfunction are associated with arrhythmia risk. Clinical evidence directly targeting rhythm outcomes with D-ribose is limited; the data derive primarily from hemodynamic improvements in CHF trials.
D-ribose is a direct substrate for mitochondrial ATP synthesis via the pentose phosphate pathway. Published peer-reviewed reviews confirm that supplemental D-ribose improves cellular processes in conditions of mitochondrial dysfunction by providing substrate to bypass the rate-limiting G6PDH step and increase PRPP for ATP production.
Skeletal muscle ATP is severely depleted by high-intensity exercise, and recovery can take days. A double-blind, crossover study (n=26) of 10 g/day D-ribose showed improved exercise performance and reduced creatine kinase versus control. A separate RCT in college students reported reduced delayed-onset muscle soreness (DOMS) with 15 g D-ribose dosing.
Clinical evidence shows D-ribose (60 g/day) significantly extended exercise duration to ischemia in CAD patients and improved exercise tolerance in ischemic heart disease patients in a 6-month RCT. In healthy athletes, results are mixed, with one study reporting increased power output at 20 g/day but others showing no significant effect.
Post-viral conditions such as Long COVID and ME/CFS are associated with altered mitochondrial function and impaired cellular energy metabolism. A 2025 integrative medicine review identified D-ribose as exceptional at restoring pre-viral energy levels. The underlying CFS evidence base (two open-label trials in 41 and 257 patients) supports energy, mental clarity, and sleep improvements relevant to post-viral fatigue.
In the 2006 (n=41) and 2012 (n=257) open-label CFS/FMS clinical studies, 'sleep' was one of the five VAS domains showing statistically significant improvement with 15 g/day D-ribose. The 2006 pilot reported a ~29% improvement in sleep quality. These findings are limited by open-label, uncontrolled designs.
Body systems that Alpha D-ribofuranose may help support.
Go back